Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Guiliang Wang, Yan Liu, Ping Qiu, Shu-Feng Zhou, Linfang Xu, Ping Wen, Jianbo Wen & Xianzhong Xiao. (2015) Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. Drug Design, Development and Therapy 9, pages 2839-2846.
Read now
Read now
Articles from other publishers (32)
Qiqi Ning, Tongwang Yang, Xianghua Guo, Yanxiang Huang, Yuxue Gao, Mengcheng Liu, Pengxiang Yang, Yuanyue Guan, Ning Liu, Yang Wang & Dexi Chen. (2023)
CHB
patients with
rtA181T
‐mutated
HBV
infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes
. Journal of Viral Hepatitis 30:12, pages 951-958.
Crossref
Crossref
Wen-Ting Peng, Chuan Jiang, Fei-Lan Yang, Nian-Qi Zhou, Ke-Yu Chen, Jin-Qing Liu, Shi-Fang Peng & Lei Fu. (2023)
Tenofovir amibufenamide
vs
tenofovir alafenamide for treating chronic hepatitis B: A real-world study
. World Journal of Gastroenterology 29:44, pages 5907-5918.
Crossref
Crossref
Wenting Peng, Huimin Gu, Da Cheng, Keyu Chen, Cichun Wu, Chuan Jiang, Jinqing Liu, Shifang Peng & Lei Fu. (2023) Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Frontiers in Microbiology 14.
Crossref
Crossref
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo & Antonio Craxì. (2022) Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses 14:5, pages 986.
Crossref
Crossref
Chunmei Li, Hui Li, Ming Gong & Jia Wei. (2022) Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate. Clinical Case Reports 10:3.
Crossref
Crossref
Yeqiong Zhang, Wenxiong Xu, Xiang Zhu, Xuejun Li, Jianguo Li, Xin Shu, Jing Lai, Junqiang Xie, Chan Xie & Liang Peng. (2021) The 48‐week safety and therapeutic effects of tenofovir alafenamide in hbv‐related acute‐on‐chronic liver failure: A prospective cohort study. Journal of Viral Hepatitis 28:4, pages 592-600.
Crossref
Crossref
Tomoya Sano, Takumi Kawaguchi, Tatsuya Ide, Keisuke Amano, Reiichiro Kuwahara, Teruko Arinaga-Hino & Takuji Torimura. (2021) Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. Life 11:3, pages 263.
Crossref
Crossref
Shi‐Chi Wen, Chi‐Chang Tsai, Lung‐Chih Cheng, Chien‐Wei Huang & Wu‐Hsien Kuo. (2020) Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: A preliminary finding. Advances in Digestive Medicine 8:1, pages 10-18.
Crossref
Crossref
Terry Cheuk-Fung Yip, Jimmy Che-To Lai & Grace Lai-Hung Wong. (2020) Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. Journal of Gastroenterology 55:11, pages 1023-1036.
Crossref
Crossref
Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn & Seung Up Kim. (2020) Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. Journal of Viral Hepatitis 27:9, pages 932-940.
Crossref
Crossref
Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho & Suzane Kioko Ono. (2020) Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. Journal of Gastroenterology 55:5, pages 496-514.
Crossref
Crossref
Xinhui Wang, Xiaoli Liu, Zhibo Dang, Lihua Yu, Yuyong Jiang, Xianbo Wang & Zhiyun Yan. (2020) Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut and Liver 14:2, pages 232-247.
Crossref
Crossref
Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Becky Wing‐Yan Yuen, Yee‐Kit Tse, Hester Wing‐Sum Luk, Terry Cheuk‐Fung Yip, Vicki Wing‐Ki Hui, Lilian Yan Liang, Grace Chung‐Yan Lui & Henry Lik‐Yuen Chan. (2019) An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017. Hepatology 71:2, pages 444-455.
Crossref
Crossref
Tao Li, Jing Li, Yang Yang, Yilin Han, Dirong Wu, Tao Xiao, Yang Wang, Ting Liu, Yonglong Zhao, Yongjun Li, Zeqin Dai & Xiaozhong Fu. (2019) Synthesis, pharmacological evaluation, and mechanistic study of adefovir mixed phosphonate derivatives bearing cholic acid and l-amino acid moieties for the treatment of HBV. Bioorganic & Medicinal Chemistry 27:16, pages 3707-3721.
Crossref
Crossref
Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Yee-Kit Tse, Terry Cheuk-Fung Yip, Kelvin Long-Yan Lam, Grace Chung-Yan Lui, Cheuk-Chun Szeto & Vincent Wai-Sun Wong. (2018) Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Alimentary Pharmacology & Therapeutics 48:9, pages 984-992.
Crossref
Crossref
Terry Cheuk-Fung Yip, Henry Lik-Yuen Chan, Yee-Kit Tse, Kelvin Long-Yan Lam, Grace Chung-Yan Lui, Vincent Wai-Sun Wong & Grace Lai-Hung Wong. (2018) On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology 113:11, pages 1629-1638.
Crossref
Crossref
G. L.-H. Wong, W.-K. Seto, V. W.-S. Wong, M.-F. Yuen & H. L.-Y. Chan. (2018) Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Alimentary Pharmacology & Therapeutics 47:6, pages 730-737.
Crossref
Crossref
Zheng Peng, Gang Fang, Fenghui Peng, Zhiyu Pan, Zhengying Su, Wei Tian, Danrong Li & Huaxin Hou. (2017) Effects of Rubiadin isolated from Prismatomeris connata on anti-hepatitis B virus activity in vitro. Phytotherapy Research 31:12, pages 1962-1970.
Crossref
Crossref
G. L.‐H. Wong, Y.‐K. Tse, T. C.‐F. Yip, H. L.‐Y. Chan, K. K.‐F. Tsoi & V. W.‐S. Wong. (2017) Long‐term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects. Alimentary Pharmacology & Therapeutics 45:9, pages 1213-1224.
Crossref
Crossref
Jiaqian Pan, Shuangmei Tong, Lei Kang & Jing Tang. (2016) New anti-hepatitis B virus drugs under development and evaluation. Current Opinion in Infectious Diseases 29:6, pages 632-638.
Crossref
Crossref
Jia Yao, Li Zhou, Xin Hua, Ming Kong, Yu Chen & Zhongping Duan. (2016) Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study. Nutrition 32:11-12, pages 1206-1210.
Crossref
Crossref
Jenny Yeuk‐Ki Cheng, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Angel Mei‐Ling Chim, Henry Lik‐Yuen Chan & Grace Lai‐Hung Wong. (2016) Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. Hepatology 64:5, pages 1507-1517.
Crossref
Crossref
Enze Jiang, Anna Junjie Shangguan, Shuangshuang Chen, Lin Tang, Shuang Zhao & Zhenghong Yu. (2016) The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Letters 379:2, pages 262-267.
Crossref
Crossref
Wenqiang Yan, Chenze Zhang, Bi Li, Xin Xu, Miao Liang, Shun Gu, Fuhao Chu, Bing Xu, Jian Ren, Penglong Wang & Haimin Lei. (2016) A Series of Oleanolic Acid Derivatives as Anti-Hepatitis B Virus Agents: Design, Synthesis, and in Vitro and in Vivo Biological Evaluation. Molecules 21:4, pages 402.
Crossref
Crossref
Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey & Kamal Hamed. (2016)
Telbivudine
vs
tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
. World Journal of Hepatology 8:32, pages 1402.
Crossref
Crossref
Charing Ching-Ning Chong & Grace Lai-Hung Wong. (2016) Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. AIMS Medical Science 3:1, pages 162-178.
Crossref
Crossref
Xin Cheng, Weiwei Guan, Shuo Sun, Baosheng Li, Haijun Li, Fubiao Kang, Jiwen Kang, Dongliang Yang, Michael Nassal & Dianxing Sun. (2015) Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. PLOS ONE 10:12, pages e0145746.
Crossref
Crossref
Hui Wang, KeHui Liu, Bernard A. M. Fang, HaiQing Wu, FengDi Li, XiaoGang Xiang, WeiLiang Tang, GangDe Zhao, LanYi Lin, Shisan Bao & Qing Xie. (2015) Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening. Cell & Bioscience 5:1.
Crossref
Crossref
Xinyan Li, Fahong Li, Yao Zhang, Yaoyue Kang, Jie Yu, Feifei Yang, Hongyan Liu, Yanli Qin, Yuxian Huang, Richeng Mao & Jiming Zhang. (2015) Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. Biochemical and Biophysical Research Communications 464:4, pages 1185-1191.
Crossref
Crossref
Grace Lai‐Hung Wong, Yee‐Kit Tse, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip, Kelvin Kam‐Fai Tsoi & Henry Lik‐Yuen Chan. (2015) Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 62:3, pages 684-693.
Crossref
Crossref
Qi Zhang, Yun Liao, Bei Cai, Yi Li, Lixin Li, Junlong Zhang, Yunfei An & Lanlan Wang. (2015) Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology 30:2, pages 252-261.
Crossref
Crossref
G. L.-H. Wong, V. W.-S. Wong & H. L.-Y. Chan. (2014) Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. Journal of Viral Hepatitis 21:12, pages 825-834.
Crossref
Crossref